Mechanistic study of dual-function inhibitors targeting topoisomerase II and Rad51-mediated DNA repair pathway against castration-resistant prostate cancer

被引:0
|
作者
Chiang, Yi-Chang [1 ]
Leu, Wohn-Jenn [1 ]
Chen, Yi-Chin [1 ]
Ye, Pei-Chen [1 ]
Hsu, Yu-Tung [1 ]
Hsiao, Yu-Chi [1 ]
Hsu, Jui-Ling [1 ,2 ]
Chan, She-Hung [3 ]
Hsu, Lih-Ching [1 ]
Huang, Hsu-Shan [4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Guh, Jih-Hwa [1 ,12 ]
机构
[1] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan
[2] Chang Gung Mem Hosp, New Taipei Municipal TuCheng Hosp, Dept Pharm, New Taipei City, Taiwan
[3] Providence Univ, Dept Cosmet Sci, Taichung, Taiwan
[4] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Mol Biol & Drug Discovery, Taipei, Taiwan
[5] Acad Sinica, Taipei, Taiwan
[6] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan
[7] Grad Inst Med Sci, Natl Def Med Ctr, Taipei, Taiwan
[8] Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan
[9] Taipei Med Univ, Coll Pharm, PhD Program Drug Discovery & Dev Ind, Taipei, Taiwan
[10] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Mol Biol & Drug Discovery, Taipei 11031, Taiwan
[11] Acad Sinica, Taipei 11031, Taiwan
[12] Natl Taiwan Univ, Coll Med, Sch Pharm, 33, Linsen S Rd, Taipei 100, Taiwan
关键词
castration-resistant prostate cancer; dual function inhibitors; G2; arrest; Rad51; inhibition; topoisomerase II inhibitors; PTEN; CHEMOTHERAPY; DEGRADATION; PREDNISONE; ANTICANCER; EXPRESSION; ETOPOSIDE; APOPTOSIS; AGENTS; P21;
D O I
10.1002/pros.24613
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundCastration-resistant prostate cancer (CRPC) is refractory to hormone treatment and the therapeutic options are continuously advancing. This study aims to discover the anti-CRPC effects and underlying mechanisms of small-molecule compounds targeting topoisomerase (TOP) II and cellular components of DNA damage repair. MethodsCell proliferation was determined in CRPC PC-3 and DU-145 cells using anchorage-dependent colony formation, sulforhodamine B assay and flow cytometric analysis of CFSE staining. Flow cytometric analyses of propidium iodide staining and JC-1 staining were used to examine the population of cell-cycle phases and mitochondrial membrane potential, respectively. Nuclear extraction was performed to detect the nuclear localization of cellular components in DNA repair pathways. Protein expressions were determined using Western blot analysis. ResultsA series of azathioxanthone-based derivatives were synthesized and examined for bioactivities in which WC-A13, WC-A14, WC-A15, and WC-A16 displayed potent anti-CRPC activities in both PC-3 and DU-145 cell models. These WC-A compounds selectively downregulated both TOP II & alpha; and TOP II & beta; but not TOP I protein expression. WC-A13, WC-A14, and WC-A15 were more potent than WC-A16 on TOP II inhibition, mitochondrial dysfunction, and induction of caspase cascades indicating the key role of amine-containing side chain of the compounds in determining anti-CRPC activities. Furthermore, WC-A compounds induced an increase of & gamma;H2AX and activated ATR-Chk1 and ATM-Chk2 signaling pathways. P21 protein expression was also upregulated by WC-A compounds in which WC-A16 showed the least activity. Notably, WC-A compounds exhibited different regulation on Rad51, a major protein in homologous recombination of DNA in double-stranded break repair. WC-A13, WC-A14, and WC-A15 inhibited, whereas WC-A16 induced, the nuclear translocation of Rad51. ConclusionThe data suggest that WC-A compounds exhibit anti-CRPC effects through the inhibition of TOP II activities, leading to mitochondrial stress-involved caspase activation and apoptosis. Moreover, WC-A13, WC-A14, and WC-A15 but not WC-A16 display inhibitory activities of Rad51-mediated DNA repair pathway which may increase apoptotic effect of CRPC cells.
引用
收藏
页码:1549 / 1563
页数:15
相关论文
共 10 条
  • [1] Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer
    Castro, Elena
    Mateo, Joaquin
    Olmos, David
    de Bono, Johann S.
    CANCER JOURNAL, 2016, 22 (05) : 353 - 356
  • [2] Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
    Hussain, Maha
    Daignault-Newton, Stephanie
    Twardowski, Przemyslaw W.
    Albany, Costantine
    Stein, Mark N.
    Kunju, Lakshmi P.
    Siddiqui, Javed
    Wu, Yi-Mi
    Robinson, Dan
    Lonigro, Robert J.
    Cao, Xuhong
    Tomlins, Scott A.
    Mehra, Rohit
    Cooney, Kathleen A.
    Montgomery, Bruce
    Antonarakis, Emmanuel S.
    Shevrin, Daniel H.
    Corn, Paul G.
    Whang, Young E.
    Smith, David C.
    Caram, Megan V.
    Knudsen, Karen E.
    Stadler, Walter M.
    Feng, Felix Y.
    Chinnaiyan, Arul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (10) : 991 - +
  • [3] Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH
    Chang, Taihao
    Lian, Zhenpeng
    Ma, Shenfei
    Liang, Zhengxin
    Ma, Xudong
    Wen, Xiaodong
    Wang, Yanming
    Liu, Ranlu
    PROSTATE, 2023, 83 (05) : 470 - 486
  • [4] Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer
    Li, Likun
    Chang, Wenjun
    Yang, Guang
    Ren, Chengzhen
    Park, Sanghee
    Karantanos, Theodoros
    Karanika, Styliani
    Wang, Jianxiang
    Yin, Jianhua
    Shah, Parantu K.
    Takahiro, Hirayama
    Dobashi, Masato
    Zhang, Wenling
    Efstathiou, Eleni
    Maity, Sankar N.
    Aparicio, Ana M.
    Tapia, Elsa M. Li Ning
    Troncoso, Patricia
    Broom, Bradley
    Xiao, Lianchun
    Lee, Hyun-Sung
    Lee, Ju-Seog
    Corn, Paul G.
    Navone, Nora
    Thompson, Timothy C.
    SCIENCE SIGNALING, 2014, 7 (326)
  • [5] A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
    Whang, Young E.
    Armstrong, Andrew J.
    Rathmell, W. Kimryn
    Godley, Paul A.
    Kim, William Y.
    Pruthi, Raj S.
    Wallen, Eric M.
    Crane, Jeffrey M.
    Moore, Dominic T.
    Grigson, Gayle
    Morris, Karla
    Watkins, Catharine P.
    George, Daniel J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (01) : 82 - 86
  • [6] PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
    Castro, Elena
    Romero-Laorden, Nuria
    del Pozo, Angela
    Lozano, Rebeca
    Medina, Ana
    Puente, Javier
    Maria Piulats, Josep
    Lorente, David
    Isabel Saez, Maria
    Morales-Barrera, Rafael
    Gonzalez-Billalabeitia, Enrique
    Cendon, Ylenia
    Garcia-Carbonero, Iciar
    Borrega, Pablo
    Mendez Vidal, M. Jose
    Montesa, Alvaro
    Nombela, Paz
    Fernandez-Parra, Eva
    Gonzalez del Alba, Aranzazu
    Carlos Villa-Guzman, Jose
    Ibanez, Kristina
    Rodriguez-Vida, Alejo
    Magraner-Pardo, Lorena
    Perez-Valderrama, Begona
    Vallespin, Elena
    Gallardo, Enrique
    Vazquez, Sergio
    Pritchard, Colin C.
    Lapunzina, Pablo
    Olmos, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (06) : 490 - +
  • [7] A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent
    Markowski, Mark C.
    Tutrone, Ronald
    Pieczonka, Christopher
    Barnette, K. Gary
    Getzenberg, Robert H.
    Rodriguez, Domingo
    Steiner, Mitchell S.
    Saltzstein, Daniel R.
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    CLINICAL CANCER RESEARCH, 2022, 28 (13) : 2789 - 2795
  • [8] Study on the influence of metformin on castration-resistant prostate cancer PC-3 cell line biological behavior by its inhibition on PLCε gene-mediated Notch1/Hes and androgen receptor signaling pathway
    Yang, Y.
    Wu, X. -H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (08) : 1918 - 1923
  • [9] Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects
    Smith, Matthew R.
    Sandhu, Shahneen
    George, Daniel J.
    Chi, Kim Nguyen
    Saad, Fred
    Thiery-Vuillemin, Antoine
    Stahl, Olaf
    Olmos, David
    Danila, Daniel C.
    Gafanov, Rustem
    Castro, Elena
    Moon, Helen
    Joshua, Anthony M.
    Mason, Gary E.
    Espina, Byron M.
    Liu, Yan
    Lopez-Gitlitz, Angela
    Francis, Peter
    Bevans, Katherine B.
    Fizazi, Karim
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (07) : 758 - 768
  • [10] Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
    Zhao, Jimmy L.
    Antonarakis, Emmanuel S.
    Cheng, Heather H.
    George, Daniel J.
    Aggarwal, Rahul
    Riedel, Elyn
    Sumiyoshi, Takayuki
    Schonhoft, Joseph D.
    Anderson, Amanda
    Mao, Ninghui
    Haywood, Samuel
    Decker, Brooke
    Curley, Tracy
    Abida, Wassim
    Feng, Felix Y.
    Knudsen, Karen
    Carver, Brett
    Lacouture, Mario E.
    Wyatt, Alexander W.
    Rathkopf, Dana
    BRITISH JOURNAL OF CANCER, 2024, 130 (01) : 53 - 62